These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15164031)

  • 1. AIDS-vaccine firm needled by stock-exchange rules.
    Nature; 2004 May; 429(6990):335. PubMed ID: 15164031
    [No Abstract]   [Full Text] [Related]  

  • 2. Rumoured good news raises share price of vaccine company.
    Macilwain C
    Nature; 1993 Jun; 363(6428):388. PubMed ID: 8502290
    [No Abstract]   [Full Text] [Related]  

  • 3. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New SEC regulations could hinder biotech investment. US Securities and Exchange Commission.
    Bouchie A
    Nat Biotechnol; 2002 Jul; 20(7):639-40. PubMed ID: 12089533
    [No Abstract]   [Full Text] [Related]  

  • 5. Coming to terms.
    Oden DH; Wolfson JA; Marshall CW
    Nat Biotechnol; 2010 Feb; 28(2):120-2. PubMed ID: 20139940
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical research. AIDS vaccine results draw investor lawsuits.
    Cohen J
    Science; 2003 Mar; 299(5615):1965. PubMed ID: 12663890
    [No Abstract]   [Full Text] [Related]  

  • 7. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 8. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 9. April Fools--sell-side analysts discover biotechnology.
    Jacobs T
    Nat Biotechnol; 2002 Apr; 20(4):333. PubMed ID: 11923828
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV vaccine: sell-out or vote of confidence by Genentech?
    Wadman M
    Nature; 1996 Feb; 379(6568):757. PubMed ID: 8587588
    [No Abstract]   [Full Text] [Related]  

  • 11. US law threatens flow of foreign capital to biotech sector.
    Morrison C
    Nat Biotechnol; 2018 Oct; 36(10):914-915. PubMed ID: 30307931
    [No Abstract]   [Full Text] [Related]  

  • 12. Investors sought for AIDS vaccine trials.
    Science; 1996 Mar; 271(5253):1237. PubMed ID: 8638103
    [No Abstract]   [Full Text] [Related]  

  • 13. 'Money down the drain' fears for AIDS vaccine trials.
    Nature; 2003 Nov; 426(6964):220-1. PubMed ID: 14628016
    [No Abstract]   [Full Text] [Related]  

  • 14. Falling stock prices put the squeeze on biotech start-ups.
    Lehrman S
    Nature; 1995 Jan; 373(6511):178. PubMed ID: 7816117
    [No Abstract]   [Full Text] [Related]  

  • 15. Back to life.
    Smaglik P
    Nature; 2004 May; 429(6990):483. PubMed ID: 15164076
    [No Abstract]   [Full Text] [Related]  

  • 16. Icelandic biotech feels the pinch.
    Wadman M
    Nature; 2008 Oct; 455(7215):842. PubMed ID: 18938257
    [No Abstract]   [Full Text] [Related]  

  • 17. Portfolio managing for scientists.
    Sable D
    Nat Biotechnol; 2010 Oct; 28(10):1131. PubMed ID: 20944607
    [No Abstract]   [Full Text] [Related]  

  • 18. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 19. US abandons planned AIDS vaccine trial.
    Macilwain C
    Nature; 1994 Feb; 367(6462):399. PubMed ID: 8107784
    [No Abstract]   [Full Text] [Related]  

  • 20. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.